Literature DB >> 22305592

Imaging benign inflammatory syndromes.

S Ferron1, M Asad-Syed, M Boisserie-Lacroix, J Palussière, G Hurtevent.   

Abstract

Benign mastitis is a rare disease and its management is difficult. The diagnostic challenge is to distinguish it from carcinomatous mastitis. We make a distinction between acute mastitis secondary to an infection, to inflammation around a benign structure or to superficial thrombophlebitis, and chronic, principally plasma cell and idiopathic granulomatous mastitis. Imaging is often non-specific but we need to know and look for certain ultrasound, mammogram or magnetic resonance imaging (MRI) signs to give a pointer as early as possible towards a benign aetiology. A biopsy should be undertaken systematically where there is the slightest diagnostic doubt, to avoid failing to recognise a carcinomatous mastitis.
Copyright © 2011 Éditions française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22305592     DOI: 10.1016/j.diii.2011.12.002

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  3 in total

1.  Ultrasound elastography and magnetic resonance examinations are effective for the accurate diagnosis of mammary duct ectasia.

Authors:  Feixue Zhang; Dexin Yu; Mingming Guo; Qing Wang; Zhigang Yu; Fei Zhou; Meng Zhao; Feng Xue; Guangrui Shao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  A rim-enhanced mass with central cystic changes on MR imaging: how to distinguish breast cancer from inflammatory breast diseases?

Authors:  Lijun Wang; Dengbin Wang; Xiaochun Fei; Mei Ruan; Weimin Chai; Lin Xu; Xiaoxiao Li
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

3.  Incidence of inflammatory breast cancer in patients with clinical inflammatory breast symptoms.

Authors:  Yohann Dabi; Lauren Darrigues; Kelly Pons; Mylène Mabille; Issam Abd Alsamad; Rana Mitri; Dounia Skalli; Bassam Haddad; Cyril Touboul
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.